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Enteropathogenic Escherichia coli (EPEC) is a major cause of diarrheal infant death in
developing countries, and probiotic bacteria have been shown to provide health benefits
in gastrointestinal infections. In this study, we have investigated the influence of the gut
symbiont Lactobacillus reuteri on EPEC adherence to the human intestinal epithelium.
Different host cell model systems including non-mucus-producing HT-29 and mucus-
producing LS174T intestinal epithelial cell lines as well as human small intestinal biopsies
were used. Adherence of L. reuteri to HT-29 cells was strain-specific, and the mucus-
binding proteins CmbA and MUB increased binding to both HT-29 and LS174T cells.
L. reuteri ATCC PTA 6475 and ATCC 53608 significantly inhibited EPEC binding to HT-
29 but not LS174T cells. While pre-incubation of LS174T cells with ATCC PTA 6475 did
not affect EPEC attaching/effacing (A/E) lesion formation, it increased the size of EPEC
microcolonies. ATCC PTA 6475 and ATCC 53608 binding to the mucus layer resulted in
decreased EPEC adherence to small intestinal biopsy epithelium. Our findings show that
L. reuteri reduction of EPEC adhesion is strain-specific and has the potential to target
either the epithelium or the mucus layer, providing further rationale for the selection of
probiotic strains.
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INTRODUCTION
Enteropathogenic Escherichia coli (EPEC) was first reported by Bray (1945) as a cause of infant
summer diarrhea in the UK, and has since remained an important pathogen, particularly in the
developing world (Nataro and Kaper, 1998). According to a recent systematic review, EPEC is
the second most common cause (after rotavirus) of diarrheal death in children <5 years in the
world (Lanata et al., 2013). One of the major virulence traits of EPEC is its ability to adhere to
small intestinal epithelium by forming attaching/effacing (A/E) lesions. These are characterized by
intimate bacterial attachment to the host cell membrane, effacement of underlying microvilli and
polymerization of filamentous actin underneath adherent bacteria (Moon et al., 1983; Knutton
et al., 1989). A/E lesion formation causes a loss of absorptive surface and, together with other
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effects mediated by type 3 secreted EPEC effector proteins, leads
to the development of diarrhea (Viswanathan et al., 2009; Wong
et al., 2011).
Clinical studies have shown that probiotic bacteria, such
as lactobacilli can protect against intestinal infection (Sazawal
et al., 2006). In particular, Lactobacillus reuteri, a natural
inhabitant of the gastrointestinal tract of many mammals and
birds (Casas and Dobrogosz, 2000), is effective as a therapeutic
agent in acute rotavirus diarrhea in children (Shornikova et al.,
1997a,b) and has recently been shown to protect against EPEC
infection in infants (Savino et al., 2015). Several mechanisms
of how probiotic bacteria protect against pathogens have been
suggested and confirmed by in vitro studies. These include
pathogen inhibition through microbe–microbe interactions (e.g.,
competition for nutrients and binding sites, production of
antimicrobials), enhancement of epithelial barrier function (e.g.,
induction of mucins and preservation of tight junctions), and
modulation of immune responses (e.g., regulation of cytokine
expression, phagocyte, and T cell function; Lebeer et al., 2008).
Competition for binding sites, also referred to as competitive
exclusion, has been the focus of many in vitro studies (Bernet
et al., 1994; Forestier et al., 2001; Sherman et al., 2005) and
forms part of the rationale why adherence to intestinal mucosa
is considered a desirable trait for probiotic bacteria (Havenaar
et al., 1992; Tuomola et al., 2001). However, most of these studies
have been performed on human enterocyte-derived cell lines
(e.g., Caco-2, HT-29, T84) which do not produce a secreted
mucus layer (van Klinken et al., 1996; Navabi et al., 2013).
While this approach might be suitable to study the effects of
probiotics on inflammatory bowel disease or other conditions
with a compromised mucus layer (Sheng et al., 2012), it remains
unknown whether findings on non-mucus producing epithelial
cell lines can be translated to a normal intestinal mucosa where
the epithelium is protected by a thick mucus layer (Juge, 2012).
In this study, we have investigated the effect of L. reuteri
on EPEC adherence to mucus- and non-mucus-secreting
human intestinal epithelial cell lines (LS174T and HT-29 cells,
respectively) and to human small intestinal explants in an in vitro
organ culture model.
MATERIALS AND METHODS
Cell Culture
Human colon carcinoma HT-29 (ATCC HTB-38) and LS174T
cells (ATCC CL-188) were cultured in DMEM medium (Sigma)
supplemented with 10% fetal bovine serum (Sigma) and used
between passage 5 to 20 and passage 7 to 27, respectively. Cells
were grown at 37◦C in a 5% CO2 atmosphere.
Bacterial Strains and Culture Conditions
Bacterial strains used in this study are listed in Table 1. EPEC
was grown standing in LB broth overnight at 37◦C. L. reuteri
was cultured standing in an anaerobic cabinet (5% CO2, 10%
H2, and 85% N2) overnight at 37◦C in MRS broth. Bacteria were
spun down and suspended in an equivalent volume of serum-free
DMEM medium prior to infection.
Adherence Assays
Cells were seeded out in 24 well plates at a density of 105 cells
per well and grown for 6 days (HT-29) or 8 days (LS174T) to
full confluence reaching a number of approximately 106 cells
per well. For adherence assays, cell monolayers were inoculated
with around 5 × 107 L. reuteri or EPEC (50 µl of a standing
overnight culture of approximately 1 × 109 colony forming
units/ml), equaling a multiplicity of infection (MOI) of around
50 bacteria per cell. After incubation for 1 h, cells were washed
three times in PBS to remove non-adherent bacteria. Adherent
bacteria were quantified by lysing cell monolayers in 1% Triton
X-100 for 15 min and plating out serial dilutions of lysates on
MRS (L. reuteri) or LB agar plates (EPEC). In addition, bacterial
inocula and total numbers of EPEC after 1 h of incubation
were determined by plating out dilutions of the inocula and
combined cell supernatants/lysates, respectively. MRS plates were
incubated anaerobically, and LB plates were incubated aerobically
at 37◦C. Colony forming units (CFU) were determined next day.
Adherence was calculated according to the following equation: %
adhesion = (number of adherent bacteria/number of inoculated
bacteria)× 100.
Protection Assays
Two different protocols were applied for protection assays. For
short-term assays without removal of non-adherent lactobacilli,
cell monolayers were pre-incubated with 5 × 106 to 5 × 108
(equal numbers to 100-fold excess, MOI of 5 to 500) L. reuteri
for 1 or 3 h before 5 × 106 EPEC (MOI of 5) were added
for 1 h. To assess protection by adherent lactobacilli, cells were
pre-incubated with 5 × 108 L. reuteri (MOI of 500) for 4 h,
non-adherent bacteria were removed by washing, and cells were
further incubated with 5 × 106 EPEC for 1 or 3 h. At the end
of the experiment, cell viability and pH of the culture medium
were evaluated by Trypan blue stain (0.2%, Sigma) and pH
indicator sticks (pH range 4.5–10.0 at 0.5 intervals, Fisher),
respectively.
Polarized In Vitro Organ Culture (pIVOC)
This study was performed with approval from the University of
East Anglia Faculty of Medicine and Health Ethics Committee
(ref 2010/11-030). All samples were provided through the
Norwich Biorepository, which has NRES approval (ref
08/h0304/85+5). Biopsy samples from the second part of
the duodenum were obtained with informed consent during
routine endoscopy of 11 adult patients (48–82 years old). Samples
were taken from macroscopically normal areas, transported to
the laboratory in IVOC medium and processed within 1 h.
Polarized IVOC was performed as described previously (Schüller
et al., 2009). Briefly, biopsies were mounted on a membrane
filter with the mucosal side facing upward and sandwiched
between two Perspex disks with a central aperture. This assembly
was then inserted into a Snapwell support (Corning Costar).
For adherence assays, biopsies were inoculated with 2 × 107
L. reuteri or EPEC on the mucosal side and incubated for 6 h
in a 5% CO2 atmosphere at 37◦C on a rocking platform. For
protection assays, biopsies were inoculated with 109 L. reuteri
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TABLE 1 | Bacterial strains.
Strain Host Reference
Lactobacillus reuteri
ATCC PTA 6475 Human Oh et al., 2010
ATCC PTA 6475 CmbA− Human Etzold et al., 2014b
ATCC 55730 (SD2112) Human Oh et al., 2010
LMS11-3 Human Oh et al., 2010
DSM 20016 Human Oh et al., 2010
ATCC 53608 (1063) Pig Oh et al., 2010
1063N Pig MacKenzie et al., 2010
100-23C Rat Oh et al., 2010
LB54 Chicken Oh et al., 2010
EPEC
O127:H6 E2348/69 Human Levine et al., 1978
for 2 h, non-adherent lactobacilli were removed, and 2 × 107
EPEC were applied for 4 h. At the end of the experiment,
biopsies were removed from the Snapwell support, washed
three times in PBS to remove non-adherent bacteria and
mucus, unless indicated otherwise, and processed for further
analysis. For determination of adherent bacteria, biopsies
were homogenized with a sterile pestle and lysed as described
above.
Immunofluorescence Staining
Biopsy samples with preserved mucus layer were embedded in
OCT compound (Sakura), snap-frozen in a dry ice/ethanol bath
and stored at –70◦C until use. Serial sections of 7 µm were
cut with a Microm HM550 cryostat (Thermo Scientific), picked
up on poly L-lysine-coated slides and air-dried. Tissue sections
were blocked with 0.5% bovine serum albumin (BSA) in PBS for
20 min. Cells on coverslips were fixed in 3.7% formaldehyde in
PBS for 10 min or in methanol/acetone (1:1) for 4 min on ice (for
mucus staining) and blocked/permeabilized with 0.1% Tx-100
and 0.5% BSA for 20 min. Cells and cryosections were incubated
with primary antibodies (rabbit anti-CmbA (Etzold et al., 2014b),
rabbit anti-MUB (MacKenzie et al., 2010), rabbit anti-SRR (kind
gift from Donald MacKenzie), goat anti-E. coli from abcam,
mouse anti-MUC2 from Santa Cruz) for 60 min, washed and
incubated with Alexa Fluor-conjugated secondary antibodies
(Life Technologies) for 30 min. Cell nuclei and filamentous actin
were stained with DAPI (Roche) and FITC-conjugated phalloidin
(Sigma), respectively. Samples were mounted in Vectashield
(Vector Laboratories) and analyzed using a fluorescence light
microscope (Axiovert 200M, Zeiss). Formation of EPEC actin
pedestals or microcolonies was quantified from ten random
fields of view containing around 70 cells for each experimental
condition.
Scanning Electron Microscopy
Biopsies were either washed in PBS to remove the mucus
layer or fixed immediately with preserved mucus layer in 2.5%
glutaraldehyde in PBS. Samples were dehydrated through a
graded acetone series, dried using tetramethylsilane (Sigma),
mounted on aluminum stubs, sputter-coated with gold (Polaron
SC7640 sputter coater, Quorum Technologies), and viewed with
a JEOL JSM 4900 LV scanning electron microscope.
Statistical Analysis
All data are shown as means ± standard error of the mean
(SEM). Statistical analysis was performed using GraphPad Prism
software (version 5). One-way ANOVA with Tukey’s multiple
comparisons test was used to determine differences between
multiple groups. A P-value of <0.05 was considered significant.
RESULTS
Adherence of L. reuteri to Intestinal
Epithelial Cells is Host Strain-Specific
In order to investigate the adherence properties of L. reuteri
strains isolated from different hosts and select highest binders,
HT-29 cells were first incubated with different L. reuteri
strains from human, pig, chicken and rat (Table 1), or with
EPEC prototype strain E2348/69, and adherence was quantified
after 1 h. No EPEC replication was detected during this
short time period, and 97.0 ± 2.6% of inoculated bacteria
(n = 5) were recovered after incubation as evaluated by CFU
counting. As shown in Figure 1A, the L. reuteri pig isolate
ATCC 53608 showed the highest level of adherence followed
by human isolates ATCC PTA 6475 and DSM 20016, which
demonstrated comparable binding levels to EPEC. In contrast,
the human isolate ATCC 55730 and the LB54 strain from chicken
demonstrated low binding, whereas the human strain LMS11-
3 exhibited an intermediate adherence potential. Furthermore,
the rat isolate 100-23C showed low binding to HT-29 cells
compared to ATCC PTA 6475, DSM 20016, LMS11-3, and ATCC
53608 as evaluated by immunofluorescence staining (Figure 1B,
images shown for ATCC PTA 6475 and 100-23C only) and
was therefore not included in the quantitative adherence assay
shown in Figure 1A. In these assays, it was also noted that
ATCC 53608 formed extensive biofilm-like aggregates on cell
surfaces (data not shown), as previously reported in vitro
(MacKenzie et al., 2010). Based on these results, ATCC PTA
6475 (human) and ATCC 53608 (pig) were selected for further
studies as they both showed high adherence but different binding
phenotypes.
Lactobacillus reuteri binding of these strains to the host is
mediated by adhesins on the bacterial surface (Etzold and Juge,
2014) with CmbA (also known as Lar_0958) being present
in human isolates (Etzold et al., 2014b; Jensen et al., 2014)
whereas MUB is specific for pig isolates (Roos and Jonsson,
2002; MacKenzie et al., 2010; Etzold et al., 2014a). In order
to investigate the effect of these adhesins on the binding of
the selected strains (ATCC PTA 6475 and ATCC 53608) to
intestinal epithelial cells, an ATCC PTA 6475 knockout mutant in
CmbA (Etzold et al., 2014b) and an ATCC 53608-derived strain
expressing truncated MUB (1063N) (MacKenzie et al., 2010)
were compared to the wild-type strains. Here, both HT-29 cells
(which do not secrete mucus) and the goblet cell-derived cell line
LS174T secreting intestinal mucin MUC2 (Figure 2A) were used
to assess binding. Quantification of bacterial adherence indicated
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FIGURE 1 | Adhesion of L. reuteri to HT-29 cells is host strain-specific.
HT-29 cells were incubated with L. reuteri or EPEC for 1 h, and adherent
bacteria were quantified by CFU (A) and/or visualized by immunofluorescence
staining (B). (A) Adhesion is expressed as percentage of adherent bacteria
relative to the inoculum. Data are shown as means ± SEM from three
independent experiments performed in duplicate. (B) L. reuteri ATCC PTA
6475 (left) and 100-23C (right) were stained with anti-CmbA and anti-SRR
(red), respectively. Cell nuclei were counterstained with DAPI in blue. Shown
are representative images from three independent experiments performed in
duplicate. Bar = 10 µm.
impaired binding of MUB- and CmbA-deficient strains to both
HT-29 and LS174T cells as compared to their respective wild-
type strains (Figure 2B). In addition, adhesion of all strains tested
(including EPEC) was considerably higher on mucus-producing
LS174T cells compared to HT-29 cells (Figure 2B). Cell viability
and pH of the culture medium (pH 7.5) were maintained during
all incubations (data not shown).
Lactobacillus reuteri Inhibits EPEC
Binding in a Strain- and Cell-Dependent
Manner
To examine whether pre-incubation with L. reuteri reduces
intestinal EPEC adhesion, HT-29 cells were incubated with a
100-fold excess of L. reuteri ATCC PTA 6475 or ATCC 53608
for 1 or 3 h before EPEC was added for another hour. This
resulted in significantly reduced EPEC adherence to HT-29 cells
(Figure 3A). No significant inhibition of EPEC binding was
FIGURE 2 | Mucus binding proteins CmbA and MUB increase L. reuteri
adhesion to HT-29 and LS174T cells. (A) Immunofluorescence staining
demonstrating MUC2 expression (green) by LS174T but not HT-29 cells. Cell
nuclei were labeled in blue. Shown are representative images from three
independent experiments performed in duplicate. Bar = 10 µm. (B) HT-29
and LS174T cells were incubated with EPEC, or L. reuteri strains ATCC PTA
6475 or ATCC 53608 for 1 h. In addition to wild-type strains (WT), isogenic
mutants deficient in expression of the adhesin CmbA (ATCC PTA 6475
CmbA-) or MUB (ATCC 53608 MUB-) were included for comparison.
Adhesion is expressed as percentage of adherent bacteria relative to the
inoculum. Data are shown as means ± SEM from three independent
experiments performed in duplicate. ∗∗P < 0.01.
observed using a 10-fold excess or equal numbers of ATCC PTA
6475 or ATCC 53608 (Figure 3B). Similar experiments were
performed with LS174T cells, and although pre-incubation with
a 100-fold excess of L. reuteri decreased EPEC adherence to some
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FIGURE 3 | Pre-incubation with L. reuteri ATCC PTA 6475 and ATCC
53608 inhibits EPEC adherence to HT-29 but not LS174T cells.
(A) HT-29 cells were pre-incubated with a 100-fold excess of L. reuteri ATCC
PTA 6475, ATCC 53608, or left untreated (–) for 1 or 3 h before addition of
EPEC for 1 h. (B) HT-29 cells were pre-incubated with a 100-fold (100x) or
10-fold (10x) excess or equal numbers (1x) of L. reuteri ATCC PTA 6475,
ATCC 53608, or left untreated (–) for 1 h before addition of EPEC for 1 h.
(C) LS174T cells were pre-incubated with a 100-fold excess of ATCC PTA
6475, ATCC 53608 or left untreated (–) for 1 h before addition of EPEC for
1 h. Cell-associated EPEC were quantified by CFU, and adhesion is
expressed as percentage of adherent bacteria relative to the inoculum. Data
are shown as means ± SEM from three independent experiments performed
in duplicate. ∗P < 0.05, ∗∗P < 0.01.
extent, this was not as pronounced as observed with HT-29 cells
and did not reach significance (Figure 3C).
FIGURE 4 | Reduced EPEC binding to HT-29 cells is independent of
L. reuteri adherence and secreted molecules. HT-29 cells were subjected
to the following treatments before addition of EPEC for 1 h: pre-incubation
with L. reuteri for 1 h (total LR), pre-incubation with L. reuteri for 2 h and
subsequent removal of non-adherent bacteria (adherent LR), pre-incubation
with L. reuteri-conditioned medium for 2 h (supernatant), or no treatment (–).
Cell-associated EPEC were quantified by CFU, and adhesion is expressed as
percentage of adherent bacteria relative to the inoculum. Data are shown as
means ± SEM from three independent experiments performed in duplicate.
∗P < 0.05.
Adhesion of bacteria to the mucosa is generally considered
as one of the desirable criteria for the selection of probiotics
as it promotes intestinal persistence and pathogen exclusion
despite peristaltic flow (Servin, 2004). To determine whether
reduced EPEC binding was mediated by L. reuteri adhering to
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the epithelium, HT-29 cells were first incubated with a 100-fold
excess of L. reuteri ATCC PTA 6475 or ATCC 53608 for 2 h,
and in contrast to experiments described above, non-adherent
bacteria were removed by washing before addition of EPEC
for 1 h. In addition, to test the potential impact of released
antimicrobial components in the supernatant, HT-29 cells were
incubated with L. reuteri-conditioned medium (cultured with
HT-29 cells for 2 h) and EPEC for 1 h. As shown in Figure 4, none
of these treatments resulted in significant reduction of EPEC
adherence.
Increasing the pre-incubation period to 4 h promoted
L. reuteri adherence as shown by immunofluorescence staining
of ATCC PTA 6475 and ATCC 53608 bound to HT-29 and
LS174T cells (Figure 5A). Non-adherent bacteria were removed
by washing, and cells were subsequently incubated with EPEC for
1 h. Adherent ATCC PTA 6475 but not ATCC 53608 significantly
reduced EPEC binding to HT-29 cells (Figure 5B). In contrast,
no significant inhibition of EPEC adhesion was observed using
LS174T cells (Figures 5A,B) despite the higher L. reuteri binding
to this cell type as reported above. As LS174T cells secrete mucus,
it is likely that a large proportion of EPEC is located within the
mucus layer rather than bound to the epithelial cell membrane.
Therefore, CFU from cell lysates might not accurately reflect
the number of EPEC bacteria adhering to the cell surface. To
this aim, the protection assay was modified, and the incubation
time with EPEC was extended to 3 h to allow the formation of
A/E lesions. Cell-bound EPEC were subsequently identified by
fluorescent actin staining (Figure 6A), and the number of EPEC
associated with actin pedestals was determined. Quantification
of actin-linked versus total cell-associated bacteria revealed that
there was no significant difference in A/E lesion formation on
cells pre-incubated with L. reuteri and non-treated controls
(Figure 6B). However, larger clusters of A/E bacteria were
observed on LS174T cells pre-incubated with ATCC PTA 6475
(Figure 6C), and quantification of microcolony formation (five
or more bacteria per colony) at a higher magnification confirmed
that pre-incubation with ATCC PTA 6475 significantly increased
the number of A/E microcolonies as compared to ATCC 53608
and non-treated controls (Figure 6D). Cell viability and pH of the
culture medium (pH 7.5) were maintained during all incubations
(data not shown).
Lactobacillus reuteri Binds to the Mucus
Layer and Decreases EPEC Adherence
to Human Small Intestinal Biopsies
To examine whether the results obtained on cancer-derived
cell lines could be translated to human intestinal tissue, a
polarized ex vivo model using human small intestinal biopsies
was employed. Polarized in vitro organ culture (pIVOC) restricts
bacterial access to a defined mucosal surface area and therefore
allows quantification of bacterial adhesion (Schüller et al.,
2009). Adult endoscopic biopsies from the duodenum were
incubated with L. reuteri ATCC PTA 6475, ATCC 53608,
or EPEC and incubated for 6 h. Biopsies were then either
fixed with mucus layer or washed first to remove mucus and
expose the epithelium, and bacterial adherence was visualized
FIGURE 5 | Adherent L. reuteri ATCC PTA 6475 inhibits EPEC binding
to HT-29 but not LS174T cells. (A) HT-29 and LS174T cells were incubated
with L. reuteri ATCC PTA 6475 or ATCC 53608 for 4 h. Adherent L. reuteri
were visualized by immunofluorescence staining with anti-CmbA (PTA 6475)
or anti-MUB (ATCC 53608) in green. Cell nuclei were counterstained with
DAPI (blue). Merged color images of both channels are shown for HT-29 cells,
whereas black-and-white images of the green channel (L. reuteri staining) are
displayed for confluent LS174T cells for greater clarity. Shown are
representative images from three independent experiments performed in
duplicate. Bar = 10 µm. (B) HT-29 and LS174T cells were pre-incubated with
ATCC PTA 6475, ATCC 53608, or left untreated (–) for 4 h, non-adherent
bacteria were removed, and EPEC was added for 1 h. Cell-associated EPEC
were quantified by CFU, and adhesion is expressed as percentage of
adherent bacteria relative to the inoculum. Data are shown as means ± SEM
from three independent experiments performed in duplicate. ∗P < 0.05.
by scanning electron microscopy. As shown in Figure 7A,
L. reuteri was observed in the mucus layer but not on the
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FIGURE 6 | Adherent L. reuteri ATCC PTA 6475 enhances EPEC microcolony formation on LS174T cells. LS174T cells were pre-incubated with L. reuteri
ATCC PTA 6475, ATCC 53608, or left untreated (–) for 4 h, non-adherent bacteria were removed, and EPEC was added for 3 h. (A) EPEC forms actin pedestals on
LS174T cells as visualized by immunofluorescence staining (EPEC stained in red and polymerized actin in green). Representative image from four independent
experiments performed in duplicate. Bar = 10 µm. (B) Quantification of EPEC bacteria associated with actin pedestals by counting. EPEC pedestal formation is
expressed as percentage of bacteria associated with polymerized actin relative to the total number of adherent EPEC observed. Data are shown as means ± SEM
from four independent experiments performed in duplicate. (C) Pre-incubation with L. reuteri ATCC PTA 6475 results in enhanced EPEC microcolony formation
compared with non-treated samples. Adherent EPEC were visualized by immunofluorescence staining. Representative images from four independent experiments
performed in duplicate. Bar = 10 µm. (D) Quantification of EPEC microcolony formation (five or more bacteria) by counting. Microcolony formation is expressed as
percentage of bacteria associated with microcolonies relative to the total number of adherent EPEC observed. Data are shown as means ± SEM from four
independent experiments performed in duplicate. ∗∗∗P <0.001.
epithelium (images shown for ATCC PTA 6475 only), whereas
EPEC was present in both the mucus layer and on the epithelium
where A/E lesions were formed. None of the treatments visibly
affected epithelial integrity, and no cell extrusion was observed
(Figure 7A). The confinement of L. reuteri to the mucus layer
was also confirmed by immunofluorescence staining of biopsy
cryosections (Figure 7B, images shown for ATCC PTA 6475
only). For protection assays, biopsies were pre-incubated with
a 50-fold excess of L. reuteri for 2 h, non-adherent bacteria
were removed, and EPEC was added for another 4 h to enable
penetration of the mucus layer and epithelial binding. At the end
of the experiment, the mucus layer was removed by washing,
and EPEC adherence to the epithelium was quantified. As
demonstrated in Figure 7C, pre-incubation with ATCC PTA
6475 or ATCC 53608 significantly reduced EPEC adherence to
duodenal biopsy epithelium.
DISCUSSION
The gut symbiont L. reuteri is unique among probiotic bacteria in
that it resides in a range of hosts (including mammals and birds)
and can protect against disease in the species of origin (Casas
and Dobrogosz, 2000). Previous studies have demonstrated host
adaptation of L. reuteri with evolution of host-specific binding
proteins which enable rodent but not human, pig, or chicken
isolates to colonize the gut of mice (Frese et al., 2011). Similarly,
our results showed good adherence of human and pig isolates
versus reduced binding of rat and chicken isolates to human
HT-29 cells, with the exception of the human isolate ATCC
55730. This was surprising as ATCC 55730 and its plasmid-free
derivative DSM17938 have been widely used in probiotic trials
(Szajewska et al., 2014), and colonization of the human stomach
and small intestine has been shown (Valeur et al., 2004).
Lactobacillus reuteri expresses several adhesins such as the
mucus-binding proteins MUB (Roos and Jonsson, 2002), CmbA
(Etzold et al., 2014b; Jensen et al., 2014), and MapA (Miyoshi
et al., 2006) with the latter two also mediating adherence to
Caco-2 cells. Here, we show that MUB and CmbA increase
L. reuteri adherence to HT-29 cells which, like Caco-2 cells,
do not produce MUC2, the main secreted mucin in the
human intestine (van Klinken et al., 1996; Johansson et al.,
2011). A similar effect, although less pronounced, was also
observed in MUC2-secreting LS174T cells indicating binding
of MUB and CmbA to both human epithelial cell surface
molecules and secreted mucins. Interestingly, L. reuteri strains
and EPEC adhered considerably better to LS174T compared
with HT-29 cells. This might reflect a higher bacterial binding
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FIGURE 7 | L. reuteri is localized in the mucus layer and inhibits EPEC
binding to human duodenal biopsy epithelium. (A) Scanning electron
microscopy of duodenal biopsies incubated with EPEC or L. reuteri ATCC
PTA 6475 for 6 h. Biopsies were either fixed with mucus layer or washed
beforehand to expose the epithelium. Shown are representative images from
three independent experiments performed in duplicate.
(B) Immunofluorescence staining of duodenal biopsies incubated with
L. reuteri ATCC PTA 6475 for 6 h. Cryosections were stained for MUC2
(green), lactobacilli (anti-CmbA, red) and cell nuclei (blue). Shown are
representative images from four independent experiments performed in
duplicate. Bar = 10 µm. (C) Duodenal biopsies were pre-incubated with
L. reuteri ATCC PTA 6475, ATCC 53608, or left untreated (–) for 2 h,
non-adherent bacteria were removed, and EPEC was added for 4 h.
Cell-bound EPEC were quantified by CFU, and adherence is expressed as
CFU per biopsy. Data are shown as means ± SEM from four independent
experiments performed in duplicate. ∗P < 0.05, ∗∗P < 0.01.
affinity to mucus compared with the epithelial surface, as
previously demonstrated for commonly used probiotic strains
on human intestinal tissue pieces and mucus (Ouwehand et al.,
2002).
One suggested mechanism of probiotic protection is
competitive exclusion where probiotics and pathogens compete
for binding sites on the epithelial surface. This generally requires
pre-incubation (preventive treatment) as pathogen displacement
by lactobacilli is seldom observed (Lebeer et al., 2008). While
no such studies have been performed on L. reuteri and EPEC
so far, L. acidophilus has been shown to inhibit EPEC binding
to Caco-2 cells when pre-incubated at equal numbers (Bernet
et al., 1994). Similarly, pre-incubation with L. rhamnosus or
L. acidophilus at a 1,000-fold or 10-fold excess, respectively,
reduced EPEC adherence to polarized T84 cells (Sherman
et al., 2005), and L. rhamnosus inhibited EPEC adherence to
Caco-2 cells when used at a 10-fold excess (Forestier et al.,
2001). In addition, pre-incubation with L. acidophilus or
L. rhamnosus inhibited adherence of the related A/E pathogen
enterohemorrhagic E. coli to HT-29 cells at a 1,000-fold excess
(Kim et al., 2008). Therefore, our findings that a pre-incubation
with L. reuteri at a 100-fold excess decreases EPEC adherence
to HT-29 cells, are in agreement with previous studies on
other Lactobacillus species. In the conditions of the short
term protection assay, the effect was not solely reliant on the
adhesion of L. reuteri strains to the cell surface, suggesting
that steric hindrance may also play a role (Lebeer et al.,
2008).
Other probiotic mechanisms of microbe–microbe interactions
apart from competitive exclusion include production of
antimicrobial compounds. Previous studies have demonstrated
that lactic acid produced by lactobacilli has a bactericidal
effect against EHEC and Salmonella Typhimurium (Ogawa
et al., 2001; De Keersmaecker et al., 2006). In addition to
lactic acid, some L. reuteri strains produce the antimicrobial
substance reuterin during glycerol fermentation (Talarico et al.,
1988). These compounds did not appear to be involved in
the observed inhibitory effect in our experimental model as
L. reuteri-conditioned media were not sufficient to reduce EPEC
adherence.
In contrast to static cell culture models, peristaltic movement
and flow rapidly clear non-adherent bacteria from the gut
(Servin, 2004). Modification of the cell culture model to allow
efficient adherence of L. reuteri supported two mechanisms to
reduce EPEC infection which were evident for strain ATCC
PTA 6475 only. Firstly, adherent ATCC PTA 6475 reduced
EPEC adhesion to HT-29 cells suggesting blockage of specific
binding sites. This effect was not observed for ATCC 53608 which
showed aggregative binding to distinct cells, whereas ATCC
PTA 6475 was uniformly distributed. Auto-aggregation of ATCC
53608 might prevent efficient spread and blockage of cell surface
receptors in contrast to non-aggregating ATCC PTA 6475. In
contrast to HT-29 cells, no inhibition of EPEC binding was
observed on LS174T cells. This difference could be explained
by direct contact of L. reuteri with epithelial EPEC receptors
on HT-29 cells while contact with the mucus layer on LS174T
cells would not directly compete with EPEC adherence to the
epithelium. However, a significantly higher number of EPEC
microcolonies was observed with ATCC PTA 6475 compared
with LS174T cells pre-incubated with ATCC 53608 and the non-
treated control. Although both L. reuteri strains appeared to bind
similarly to LS174T cells, different adherence to the epithelial
surface (as opposed to the overlying mucus), as observed on HT-
29 cells, may provide a second mechanism by which ATCC PTA
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6475 could potentially inhibit EPEC microcolony dispersal and
cell-to-cell spread by blockage of cell surface receptors.
Furthermore, both ATCC PTA 6475 and ATCC 53608
significantly inhibited EPEC binding to duodenal biopsy
epithelium. As both L. reuteri strains were shown to be confined
to the mucus layer, this suggests that, in presence of a preserved
mucus layer, the inhibitory effect of L. reuteri strains is exerted
at the mucus interface rather than the epithelial surface. The
exact mechanism of this effect still remains to be elucidated,
but it is conceivable that L. reuteri binding to the mucus layer
could result in a stronger physical barrier against EPEC infection.
Contrasting results in LS174T cells and duodenal biopsy tissue
might be explained by differences in mucus organization and
composition. Notably, LS174T cells present a “goblet cell-
like” phenotype and produce MUC2 but also demonstrate an
aberrant secretion of human gallbladder mucin and gastric
MUC5AC often associated with colon cancer (van Klinken et al.,
1996; Bartman et al., 1999). This is in contrast to human
duodenal biopsy mucosa which presents a single layer of secreted
MUC2.
In summary, our studies have demonstrated that L. reuteri
can reduce EPEC infection by several mechanisms which
include competitive exclusion at the mucus or epithelial
level or via potential inhibition of microcolony dispersal
and cell-to-cell spread. These effects were strain-specific and
dependent on the intestinal model system used, highlighting
the need for a careful choice of experimental models when
selecting potential probiotic strains. Alterations in the mucus
layer have been reported in a number of infectious and
inflammatory diseases, often facilitating bacterial access to
the epithelial surface. Whether individuals present with
a healthy or compromised mucus layer may therefore
influence the rationale for selecting specific probiotic
strains.
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